Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.

Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, Plesa G, Chen F, Davis MM, Hwang WT, Young RM, Brogdon JL, Isaacs R, Pruteanu-Malinici I, Siegel DL, Levine BL, June CH, Milone MC.

J Clin Invest. 2019 Mar 21;129(6):2210-2221. doi: 10.1172/JCI126397.

2.

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.

Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, Levine JE, Qayed M, Grupp SA, Boyer M, De Moerloose B, Nemecek ER, Bittencourt H, Hiramatsu H, Buechner J, Davies SM, Verneris MR, Nguyen K, Brogdon JL, Bitter H, Morrissey M, Pierog P, Pantano S, Engelman JA, Winckler W.

Nat Med. 2018 Oct;24(10):1504-1506. doi: 10.1038/s41591-018-0146-z. Epub 2018 Oct 1.

PMID:
30275569
3.

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.

Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O'Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, Dorfmeier C, Chen F, Tian L, Parakandi H, Gupta M, Young RM, Johnson FB, Kulikovskaya I, Liu L, Xu J, Kassim SH, Davis MM, Levine BL, Frey NV, Siegel DL, Huang AC, Wherry EJ, Bitter H, Brogdon JL, Porter DL, June CH, Melenhorst JJ.

Nat Med. 2018 May;24(5):563-571. doi: 10.1038/s41591-018-0010-1. Epub 2018 Apr 30.

4.

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.

Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH.

N Engl J Med. 2017 Dec 28;377(26):2545-2554. doi: 10.1056/NEJMoa1708566. Epub 2017 Dec 10.

5.

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV.

Sci Transl Med. 2017 Jul 19;9(399). pii: eaaa0984. doi: 10.1126/scitranslmed.aaa0984.

6.

Rationale for anti-GITR cancer immunotherapy.

Knee DA, Hewes B, Brogdon JL.

Eur J Cancer. 2016 Nov;67:1-10. doi: 10.1016/j.ejca.2016.06.028. Epub 2016 Aug 31. Review.

7.

Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.

Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace AK, Dentchev T, Thekkat P, Loew A, Boesteanu AC, Cogdill AP, Chen T, Fraietta JA, Kloss CC, Posey AD Jr, Engels B, Singh R, Ezell T, Idamakanti N, Ramones MH, Li N, Zhou L, Plesa G, Seykora JT, Okada H, June CH, Brogdon JL, Maus MV.

Sci Transl Med. 2015 Feb 18;7(275):275ra22. doi: 10.1126/scitranslmed.aaa4963.

8.

OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.

Bulliard Y, Jolicoeur R, Zhang J, Dranoff G, Wilson NS, Brogdon JL.

Immunol Cell Biol. 2014 Jul;92(6):475-80. doi: 10.1038/icb.2014.26. Epub 2014 Apr 15.

PMID:
24732076
9.

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.

Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, Wilson NS, Dranoff G, Brogdon JL.

J Exp Med. 2013 Aug 26;210(9):1685-93. doi: 10.1084/jem.20130573. Epub 2013 Jul 29.

10.

Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function.

Brogdon JL, Xu Y, Szabo SJ, An S, Buxton F, Cohen D, Huang Q.

Blood. 2007 Feb 1;109(3):1123-30. Epub 2006 Sep 28.

PMID:
17008546
11.

CD4-dependent signaling is required for a late checkpoint during Th2 development associated with resistance to activation-induced cell death.

Tatari-Calderone Z, Brogdon JL, Tinsley KW, Ramezani A, Leitenberg D.

J Immunol. 2005 Nov 1;175(9):5629-36.

12.

CD4 raft association and signaling regulate molecular clustering at the immunological synapse site.

Balamuth F, Brogdon JL, Bottomly K.

J Immunol. 2004 May 15;172(10):5887-92.

14.

Activation of CD4 T cells by Raf-independent effectors of Ras.

Czyzyk J, Brogdon JL, Badou A, Henegariu O, Preston Hurlburt P, Flavell R, Bottomly K.

Proc Natl Acad Sci U S A. 2003 May 13;100(10):6003-8. Epub 2003 Apr 29.

15.
16.

Resident lung antigen-presenting cells have the capacity to promote Th2 T cell differentiation in situ.

Constant SL, Brogdon JL, Piggott DA, Herrick CA, Visintin I, Ruddle NH, Bottomly K.

J Clin Invest. 2002 Nov;110(10):1441-8.

17.

Supplemental Content

Loading ...
Support Center